Shionogi & Co., Ltd announces that Naldemedine meets the primary endpoint in a Phase 3 study for the treatment of opiod-induced constipation
30 Mar 2015
30.03.2015 Shionogi & Co., Ltd announces that Nademedine meets the primary endpoint in a Phase 3 study for the treatment of opiod-induced constipation
© Shionogi B.V. 2020. All rights reserved. This website is owned by Shionogi B.V. Registered with the Trade Register of the Dutch Chamber of Commerce under number 73229180. Registered address is Kingsfordweg 151, 1043GR, Amsterdam, the Netherlands.
Report Side Effect
Just to let you know, you are now moving to another website this is not under our control and Shionogi Limited is not responsible for its contents.